Compare Cytokinetics Inc (CYTK) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Cytokinetics Inc trades at $82.48 (market cap $11.12B), while YieldMax TSLA Option Income Strategy ETF trades at $26.8. The key difference: Cytokinetics Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | TSLY | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $87.26 | $48.25 |
52-Week Low | $33.23 | $26.16 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
TSLY trades at $26.73, down 2.52% today amid bearish technical signals with moving averages indicating selling pressure. The ETF maintains aggressive weekly dividend distributions, with recent payouts ranging from $0.28 to $0.52 per share. Technical indicators show neutral oscillators but overall bearish momentum, with key support at $26 and resistance at $27.
The high-yield strategy faces capped upside potential from covered call overlays while generating substantial income. Key risks include volatility exposure to underlying TSLA performance and return of capital distributions. June catalysts from Tesla's shareholder meeting represent near-term price drivers for the fund.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
